Clinical trials: Lewy Body Disease
Lewy Body Dementia
Safety and Efficacy of AR1005 in Patients with Lewy Body Disease
This study is a phase 2a, single-center, double-blind and randomized clinical trial that evaluates the safety and efficacy of AR1005 administration in 60 patients with cognitive impairment due to Lewy body disease.
- Trial name
- AR1005 (NCT06537076)
- Testing
- AR1005, Rivastigmine 3 mg
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Dementia
Circadian Rhythm and Other Factors in Memory Clinic Patients
The CIRCAME study is a bicentric study of patients from 2 memory clinics in Paris. The main objective is to identify circadian rhythm components and other individual risk factors (sociodemographic, behavioral, and health related…
- Trial name
- CIRCAME (NCT05977712)
- Testing
- Questionnaire, Clinical examination, Accelerometer port
- Where
- 2 sites in France
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Dementia, Alzheimer Disease
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease…
- Conditions
- Dementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia
- Trial name
- CRND TorCA (NCT06529744)
- Where
- 4 sites in Canada
- Volunteers
- 500 people
- Sponsor
- University Health Network, Toronto
Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the…
- Trial name
- NCT04924101
- Testing
- Pembrolizumab, MK-4830, Boserolimab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Cell Carcinoma
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC).
- Trial name
- NCT02853344
- Testing
- Pembrolizumab
- Volunteers
- 275 people
- Sponsor
- Merck Sharp & Dohme LLC
Dementia With Lewy Bodies
Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies
This study will be conducted to compare Irsenontrine to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus…
- Trial name
- NCT03467152
- Testing
- Irsenontrine
- Where
- 74 sites in United States, France and 5 more
- Volunteers
- 326 people
- Sponsor
- Eisai Inc.
Dementia With Lewy Bodies, Alzheimer Disease
Self and Autobiographical Memory in Dementia With Lewy Bodies and Alzheimer Disease: a Behavioral and Multimodal Neuroimaging Study
The present project aims at exploring different components of Self-consciousness or 'the Self', such as autobiographical memory, self-concept and subjective sense of Self, in dementia with Lewy Bodies (DLB) compared to…
- Conditions
- Dementia With Lewy Bodies, Alzheimer Disease, Self, Autobiographical Memory
- Trial name
- SELF-MCL (NCT04616287)
- Testing
- Neuropsychological assessment and Multimodal brain MRI
- Where
- France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Hepatocellular Carcinoma
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
This is a efficacy and safety study of pembrolizumab (MK-3475, KEYTRUDA®) as monotherapy in participants with hepatocellular carcinoma (HCC) in two cohorts: participants with advanced HCC and with no curative option after disease…
- Trial name
- NCT02702414
- Testing
- Pembrolizumab
- Volunteers
- 156 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with…
- Trial name
- NCT02027961
- Testing
- Durvalumab, Dabrafenib, Trametinib
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 68 people
- Sponsor
- MedImmune LLC
RT-QuIC
Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease
Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on.
- Trial name
- NCT07498686
- Where
- 2 sites in China
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Idiopathic Anosmia, Idiopathic Hyposmia
Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA
Test of early warning signs and RT-QuIC in patients with idiopathic olfactory dysfunction
- Conditions
- Idiopathic Anosmia, Idiopathic Hyposmia, Idiopathic Olfactory Dysfunction
- Trial name
- AROMA (NCT05740683)
- Testing
- RT-QuiC
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Danish Dementia Research Centre
Melanoma
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study.
- Trial name
- NCT04305054
- Testing
- Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab
- Where
- 60 sites in United States, Argentina and 12 more
- Volunteers
- 335 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Comparing Antipsychotic Medications in LBD Over Time
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or…
- Trial name
- CAMELOT (NCT05590637)
- Testing
- Pimavanserin, Quetiapine
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Esophageal Squamous Cell Carcinoma
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants…
- Trial name
- NCT05319730
- Testing
- Paclitaxel, Irinotecan, Pembrolizumab
- Where
- 58 sites in United States, Brazil and 12 more
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04305041
- Testing
- Pembrolizumab, Quavonlimab, Vibostolimab
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment, Alzheimer Disease
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Alzheimer Dementia, Dementia, Vascular
- Trial name
- NCT03538522
- Testing
- N-831(Traneurocin) 10 mg QD, NA-831 (Traneurocin) 20 mg QD, NA-831 (Traneurocin) 40 mg QD
- Where
- 2 sites in New Zealand
- Volunteers
- 126 people
- Sponsor
- Biomed Industries, Inc.
Head and Neck Squamous Cell Carcinoma, Cancer
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced
- Trial name
- NCT03383094
- Testing
- Pembrolizumab, Radiation therapy, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 126 people
- Sponsor
- Loren Mell, MD
Alzheimer Disease, Lewy Body Dementia (LBD)
The Role of Advanced Electroencephalographic Data as Marker of Pathology and Prognosis in Primary Dementias
The study aims to use advanced brainwave recordings of electroencephalogram (EEG) to understand early signs of Alzheimer's disease (AD) in people with mild memory problems, known as amnestic Mild Cognitive Impairment (MCI).
- Conditions
- Alzheimer Disease, Lewy Body Dementia (LBD), Mild Alzheimer Disease, Frontotemporal Dementia (FTD)
- Trial name
- NCT06826157
- Testing
- Electroencephalogram, 3 Tesla MRI, Apolipoprotein E genetic test
- Where
- Italy
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Neoplasm Metastasis
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or…
- Trial name
- NCT06460961
- Testing
- MK-6837, Pembrolizumab, Rescue Medications
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- Conditions
- Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer
- Trial name
- NCT02628067
- Testing
- pembrolizumab
- Volunteers
- 1,609 people
- Sponsor
- Merck Sharp & Dohme LLC